Capture_brand and logo.PNG
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023
February 22, 2024 07:00 ET | Morphic Therapeutic
MORF ends '23 with $700 million, cash into 2H27; MORF-057 EMERALD-2 UC trial enrolling on target; to begin Ph 2 GARNET trial of 057 in Crohn's disease 1H24
Capture_brand and logo.PNG
Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 16:05 ET | Morphic Therapeutic
Morphic CEO. Praveen Tipirneni, MD, to present at JP Morgan Healthcare Conference January 10, 2024
Capture_brand and logo.PNG
Morphic to Present at November Investor Conferences
November 10, 2023 08:00 ET | Morphic Therapeutic
WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Capture_brand and logo.PNG
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
November 03, 2023 07:00 ET | Morphic Therapeutic
-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued enrollment on target in EMERALD-2 Phase 2b trial of...
Capture_brand and logo.PNG
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
October 09, 2023 08:00 ET | Morphic Therapeutic
WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Capture_brand and logo.PNG
Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence
September 26, 2023 16:10 ET | Morphic Therapeutic
WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Morphic Holdings Inc. (Nasdaq: MORF) today announced that Chief Executive Officer Dr. Praveen Tipirneni suffered an emergent medical event and is...
Capture_brand and logo.PNG
Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023
September 22, 2023 17:30 ET | Morphic Therapeutic
-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures- -Clinical improvement consistently seen...
Capture_brand and logo.PNG
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
August 29, 2023 08:00 ET | Morphic Therapeutic
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Capture_brand and logo.PNG
Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 09, 2023 16:05 ET | Morphic Therapeutic
WALTHAM, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious...
Capture_brand and logo.PNG
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
August 03, 2023 07:05 ET | Morphic Therapeutic
-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Greater...